Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $573.01 million. The enterprise value is $510.12 million.
Important Dates
The next confirmed earnings date is Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 74.51 million shares outstanding. The number of shares has increased by 37.88% in one year.
| Current Share Class | 74.51M |
| Shares Outstanding | 74.51M |
| Shares Change (YoY) | +37.88% |
| Shares Change (QoQ) | +3.49% |
| Owned by Insiders (%) | 3.96% |
| Owned by Institutions (%) | 36.99% |
| Float | 57.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.05 |
| P/TBV Ratio | 7.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.91, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.91 |
| Quick Ratio | 8.78 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.67% and return on invested capital (ROIC) is -33.34%.
| Return on Equity (ROE) | -68.67% |
| Return on Assets (ROA) | -28.84% |
| Return on Invested Capital (ROIC) | -33.34% |
| Return on Capital Employed (ROCE) | -43.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 31 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.38% in the last 52 weeks. The beta is 0.57, so CRVS's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -9.38% |
| 50-Day Moving Average | 6.52 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 61.82 |
| Average Volume (20 Days) | 1,020,290 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.54M |
| Pretax Income | -45.14M |
| Net Income | -45.14M |
| EBITDA | -35.45M |
| EBIT | -35.54M |
| Earnings Per Share (EPS) | -$1.02 |
Full Income Statement Balance Sheet
The company has $74.41 million in cash and $1.08 million in debt, giving a net cash position of $73.32 million or $0.98 per share.
| Cash & Cash Equivalents | 74.41M |
| Total Debt | 1.08M |
| Net Cash | 73.32M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 80.23M |
| Book Value Per Share | 1.08 |
| Working Capital | 67.28M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$28.83 million and capital expenditures -$149,000, giving a free cash flow of -$28.98 million.
| Operating Cash Flow | -28.83M |
| Capital Expenditures | -149,000 |
| Free Cash Flow | -28.98M |
| FCF Per Share | -$0.39 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.88% |
| Shareholder Yield | -37.88% |
| Earnings Yield | -7.74% |
| FCF Yield | -4.97% |
Analyst Forecast
The average price target for CRVS is $13.75, which is 78.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.75 |
| Price Target Difference | 78.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |